Related Experiment Video
Updated: Feb 7, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
MiR-26a inhibits thyroid cancer cell proliferation by targeting ARPP19
Yanping Gong1, Wenshuang Wu1, Xiuhe Zou1
1Department of Thyroid and Parathyroid Surgery Center, West China Hospital, Sichuan University Sichuan 610041, China.
Abstract:
miRNA, which involves in pathogenesis of thyroid cancer via different targets, has been found aberrantly expressed in thyroid cancer. Modes of actions of miR-26a in papillary thyroid carcinoma (PTC), however, have not been fully understood to this date. In vitro results obtained from this research confirmed miR-26a was down-regulated in PTC cells (i.e. TPC-1 and BCPAP) where the down-regulation of miR-26a was found to be able to promote cell proliferation. In order to explore the mechanisms, potential targets of miR-26a were postulated: cAMP regulated phosphoprotein 19 (ARPP19) turned out to be the target of miR-26a and it was by depleting ARPP19 was the cell proliferation be suppressed. This suggested that miR-26a regulated cell proliferation by targeting ARPP19. In addition, such a depletion of ARPP19 sensitized PTC cells to tamoxifen (TMX) treatment. The above findings indicated miR-26a was a target of interest regarding the treatment of refractory thyroid carcinomas.
Insights
MicroRNA-26a (miR-26a) is downregulated in papillary thyroid cancer (PTC), promoting cell proliferation by targeting ARPP19. Restoring miR-26a may offer new treatments for refractory thyroid cancer.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Aberrant microRNA (miRNA) expression is implicated in thyroid cancer pathogenesis.
- The specific roles and mechanisms of miR-26a in papillary thyroid carcinoma (PTC) remain incompletely understood.
Purpose of the Study:
- To investigate the function and molecular targets of miR-26a in papillary thyroid carcinoma (PTC) cells.
- To explore the potential of miR-26a as a therapeutic target for refractory thyroid cancers.
Main Methods:
- In vitro studies using PTC cell lines (TPC-1 and BCPAP).
- Analysis of miR-26a expression levels.
- Investigation of miR-26a's effect on cell proliferation.
- Identification and validation of ARPP19 as a direct target of miR-26a.
- Assessment of tamoxifen (TMX) sensitivity following ARPP19 depletion.
Main Results:
- miR-26a was found to be significantly downregulated in PTC cell lines.
- Downregulation of miR-26a promoted cell proliferation in PTC cells.
- ARPP19 was identified as a direct target of miR-26a, and its depletion suppressed cell proliferation.
- Depletion of ARPP19 sensitized PTC cells to tamoxifen (TMX) treatment.
Conclusions:
- miR-26a regulates PTC cell proliferation by targeting ARPP19.
- miR-26a represents a potential therapeutic target for treating refractory thyroid carcinomas, possibly in conjunction with tamoxifen.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Feedback Inhibition
Cells Coordinate Growth and Proliferation
The Thyroid Gland
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
Abnormal Proliferation
Functions of Thyroid Hormones
TH is indispensable for the normal development and maturation of the skeletal, muscular, and nervous systems during fetal and childhood growth. It facilitates bone mineral turnover and regulates protein synthesis in developing tissues, contributing significantly to overall growth and...

